Shots:

• The companies collaborated to develop Foundation Medicine’s tissue & blood-based assays as CDx for Retevmo & other therapies in Loxo Oncology at Lilly’s pipeline. The companies will evaluate the use of FoundationOne CDx for metastatic RET fusion across tumors who may be eligible for Lilly’s Retevmo in the US & EU
• The collaboration will use Foundation Medicine’s deep regulatory & genomics expertise & also helps to optimize Lilly’s therapy development for cancer patients
• Retevmo has been approved in the US in May 2020 & is used to treat metastatic RET fusion-positive NSCLC and for adult and pediatric patients aged ≥12yrs. with advanced or metastatic RET-mutant MTC

Ref: Businesswire | Image: Eli Lilly